HUBUNGAN KADAR D-DIMER DAN NEUTROFIL LYMPHOCYTE RATIO DENGAN TINGKAT KEPARAHAN COVID-19 DI RS TUGUREJO SEMARANG
Abstract
ABSTRACT
Treatment and management of blood clotting disorders in Covid-19 patients when they have just been admitted to the hospital must be considered even if no bad manifestations are found due to increased D-dimer levels. Initial indications obtained from the hemostasis laboratory, D-dimer levels are very important to use to calculate the degree of risk and survival of Covid-19 patients. Therefore, this research was carried out with the aim of assessing the relationship between D-dimer levels and Neutrophil lymphocyte ratio with the severity level in Covid-19 patients at Tugurejo Hospital, Semarang. The type of research used in this research is analytical observational with a cross sectional design. This approach was carried out to determine the relationship between D-dimer levels and Neutrophil lymphocyte ratio with the severity of Covid-19 patients at Tugurejo Hospital, Semarang, Central Java. The majority of Covid-19 patients at Tugurejo Hospital Semarang had increased D-Dimer levels, which could indicate a potential disturbance in the blood clotting system. the majority of patients, 95.5%, showed a risky NLR (≥3.3). Most of the patients treated at Tugurejo Hospital Semarang experienced severe levels of severity. There is a significant pattern between the severity of Covid-19 patients and D-Dimer levels, where higher levels of severity tend to be associated with higher D-Dimer levels. There is a significant relationship between NLR and patient severity, with a significance value of 0.000. Research findings show that the majority of Covid-19 patients at Tugurejo Hospital Semarang experienced increased D-Dimer levels, reaching 93.2%. Elevated NLR reflects high levels of inflammation and an active immune system response. serious impact of this disease on the hospital. There is a significant relationship between D-Dimer levels and the severity of Covid-19 patients at Tugurejo Hospital Semarang with a significance of 0.000 or P<0.05 and there is a significant relationship between NLR and the severity of Covid-19 patients with a significance of 0.000 or P< 0.05
Downloads
References
WHO. 2020b. Global surveillance for COVID-19 disease caused by human infection with the 2019 novel coronavirus. Geneva: World Health Organization.
Zhang C, Shi L, W. F. 2020. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; published online March 4.Geneva ; WHO.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. L. Lancet., 395(10223).
Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Khie, L., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, O. M., Yunihastuti, E., Penanganan, T., New, I., … Cipto, R. 2020. Coronavirus Disease 2019 : Tinjauan Literatur Terkini Coronavirus Disease 2019 : Review of Current Literatures. 7(1), 45–67.
Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., & Veronese, N. 2020. Coronavirus diseases (COVID-2019) current status and future perspectives: A narrative review. Int. J Environ Res Public Health. 2020;17(8):E2690, 17(8).
Henry BM, Vikse J, Benoit S, Favaloro EJ, L. G., 2020. Hyperinflammation and dearangement of reninangiotensin- aldosterone system in COVID-19: A Novel hypothesis for clinically suspected hypercoagulapthy and microvascular imunothrombosis. Clin Chim Acta immunothrombosis. Clin Chim Acta
Fenny, Dalimoenthe NZ, Noormartany, P., 2011. Prothrombin Time, Activated Partial Thromboplastin Time, Fibrinogen, dan D- dimer Sebagai Prediktor Decompensated Disseminated Intravascular Coagulation Sisseminated pada Sepsis. 2011, 43(1).
Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A. 2020. Autopsy findings and venous thromboembolism in patients withCOVID-19. Ann Intern Med.
Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazi P, Sebastian T. 2020. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.
Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, S. K. 2020 Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. Br J Haematol.
Grace, C. 2020. Manifestasi Klinis dan Perjalanan Penyakit pada Pasien Penyakit Covid-19. Majority.
Levi, M., Thachil, J., & Iba, T. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology, 7(6), e438-e440.
Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18(4), 844-847.
Guan, W. J., Ni, Z. Y., Hu, Y., et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382(18), 1708–1720.
Zhou, F., Yu, T., Du, R., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., et al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 191, 145-147.
Qin, C., Zhou, L., Hu, Z., et al. (2020). Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases, 71(15), 762-768.
Liu, Y., Du, X., Chen, J., et al. (2020). Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection, 81(1), e6-e12.
Copyright (c) 2024 Medika Alkhairaat: Jurnal Penelitian Kedokteran dan Kesehatan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with Medika Alkhairaat : Jurnal Penelitian Kedokteran dan Kesehatan agree to the following terms:
1. Authors retain copyright and grant Journal Medika Alkhairaat right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) that allows others to remix, adapt, build upon the work non-commercially with an acknowledgement of the work’s authorship and initial publication in Journal Medika Alkhairaat.
2. Authors are permitted to copy and redistribute the journal’s published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Journal Medika Alkhairaat.
